BioSpace News Archive

CartiHeal Ltd, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, which was granted Breakthrough Device Designation by the FDA last year, announced today two-year results of the pivotal IDE Study.

Tango Therapeutics Inc. today announced that Barbara Weber, MD, President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a panel on synthetic lethality in cancer therapeutics at the 12th Annual Wedbush PacGrow Healthcare Conference on Tuesday, August 10 at 11:30 AM.

Gamida Cell Ltd. today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET.

IVERIC bio, Inc. reported that on August 2, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to five newly hired employees.

Aldeyra Therapeutics, Inc. announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the BTIG Virtual Biotechnology Conference and the H.C. Wainwright Ophthalmology Virtual Conference.

Magenta Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, announced that the company will participate in the following August investor conferences

Pieris Pharmaceuticals, Inc. today announced the appointment of Tim Demuth, M.D., Ph.D. as SVP and Chief Medical Officer.

Resolve Biosciences, the pioneer in Molecular Cartography™, and ZEISS today announced a co-development collaboration to advance spatial biology applications.

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2021, on Monday, August 9, 2021, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve®, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).